Come up with a name for your new list and we'll add to it:
FAAH Pharma raised a round of funding on August 11, 2014. Investors include
TVM Capital Life Science.
FAAH Pharma is a project-focused company developing a clinical asset initially for postherpetic neuralgia. The compound is an inhibitor of fatty acid amide hydrolase or "FAAH." The asset has been test…